Last reviewed · How we verify
Gastrectomy+ chemotherapy — Competitive Intelligence Brief
phase 3
Oncology
Small molecule
Live · refreshed every 30 min
Target snapshot
Gastrectomy+ chemotherapy (Gastrectomy+ chemotherapy) — Japan Clinical Oncology Group. Gastrectomy combined with chemotherapy removes the primary gastric tumor while systemic chemotherapy targets residual and metastatic cancer cells.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Gastrectomy+ chemotherapy TARGET | Gastrectomy+ chemotherapy | Japan Clinical Oncology Group | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Gastrectomy+ chemotherapy CI watch — RSS
- Gastrectomy+ chemotherapy CI watch — Atom
- Gastrectomy+ chemotherapy CI watch — JSON
- Gastrectomy+ chemotherapy alone — RSS
Cite this brief
Drug Landscape (2026). Gastrectomy+ chemotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/gastrectomy-chemotherapy. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing